The cardiac pharmacodynamics of therapeutic doses of sparfloxacin

Clinical Therapeutics

Volumn 21, Issue 7, 1999, Pages 1171-1181

  Morganroth, Joel ^a   Hunt, Thomas ^b   Dorr, Mary Beth ^c   Magner, David ^c,d   Talbot, George H ^c  

^a Premier Research   (United States)

^b Pharmaco LSR   (United States)

^c SANOFI   (France)

^d Astra Pharmaceuticals   (United States)

Author keywords

Plasma levels; QT(c) interval; Sparfloxacin; Therapeutic doses

Indexed keywords

PLACEBO; SPARFLOXACIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SAFETY; ELECTROCARDIOGRAPHY; GASTROINTESTINAL TOXICITY; HEART; HOLTER MONITORING; HUMAN; HUMAN EXPERIMENT; MALE; NEUROTOXICITY; NORMAL HUMAN; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE;

EID: 0032798231     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)80020-X     Document Type: Article

References (10)

1. 1. Mizuki Y, Fujiwara I, Yamaguchi T. Pharmacokinetic interactions related to the chemical structures of fluoroquinolones. J Antimicrob Chemother. 1996;37(Suppl A):41-55.
2. 2. Nakashima M, Vernatsu M, Takiguchi Y. Phase I study of pyridone carboxylic acid antibacterial agent, sparfloxacin. Rinsho-Yakuri. 1991;7:1639-1684.
3. 3. Jaillon P, Morganroth J, Brumpt I, Talbot G. Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. J Antimicrob Chemother. 1996;37(Suppl A):161-167.
4. 4. Goa KL, Bryson HM, Markham A. Sparfloxacin: A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections. Drugs. 1997; 53:700-725.
5. 5. Ortqvist A, Valtonen M, Cars O, et al. Oral empiric treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin. Chest. 1996;110:1499-1506.
6. 6. Fillastre J, Montay G, Bruno R, et al. Pharmacokinetics of sparfloxacin in patients with renal impairment. Antimicrob Agents Chemother. 1994;38:733-737.
7. 7. Bazett HC. An analysis of the time-relations of electrocardiogram. Heart. 1920; 7:353-370.
8. 8. Montay G. Pharmacokinetics of sparfloxacin in human volunteers and patients: A review. J Antimicrob Chemother. 1996;37(Suppl A):27-39.
9. 9. Montay G, Bruno R, Vergniol JC, et al. Pharmacokinetics of sparfloxacin in humans after single oral administration at doses of 200, 400, 600, and 800 mg. J Clin Pharmacol. 1994;34:1071-1076.
10. c-interval prolongation. A review. Am J Cardiol. 1993; 72:23B-25B.